Sigilon Therapeutics Current Valuation vs. Shares Owned By Insiders

SGTXDelisted Stock  USD 21.11  0.33  1.54%   
Based on Sigilon Therapeutics' profitability indicators, Sigilon Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Sigilon Therapeutics' ability to earn profits and add value for shareholders.
For Sigilon Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Sigilon Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Sigilon Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Sigilon Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Sigilon Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Sigilon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sigilon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sigilon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Sigilon Therapeutics Shares Owned By Insiders vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Sigilon Therapeutics's current stock value. Our valuation model uses many indicators to compare Sigilon Therapeutics value to that of its competitors to determine the firm's financial worth.
Sigilon Therapeutics is rated below average in current valuation category among its peers. It is rated below average in shares owned by insiders category among its peers . The ratio of Current Valuation to Shares Owned By Insiders for Sigilon Therapeutics is about  3,335,877 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sigilon Therapeutics' earnings, one of the primary drivers of an investment's value.

Sigilon Current Valuation vs. Competition

Sigilon Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 178.43 Million. Sigilon Therapeutics retains roughly 28.99 Million in current valuation claiming about 16% of equities under Health Care industry.

Sigilon Shares Owned By Insiders vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Sigilon Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
28.99 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Sigilon Therapeutics

Insiders Shares

 = 

Executives Shares

+

Employees

 = 
8.69 %
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Sigilon Shares Owned By Insiders Comparison

Sigilon Therapeutics is currently under evaluation in shares owned by insiders category among its peers.

Sigilon Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Sigilon Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Sigilon Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Sigilon Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Sigilon Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Sigilon Therapeutics, Inc., a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Sigilon Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 66 people.

Sigilon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Sigilon Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Sigilon Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Sigilon Therapeutics' important profitability drivers and their relationship over time.

Use Sigilon Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sigilon Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sigilon Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Sigilon Therapeutics Pair Trading

Sigilon Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Sigilon Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sigilon Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sigilon Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sigilon Therapeutics to buy it.
The correlation of Sigilon Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sigilon Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sigilon Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sigilon Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Sigilon Therapeutics position

In addition to having Sigilon Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Funds Thematic Idea Now

Consumer Funds
Consumer Funds Theme
Funds or Etfs that invest in consumer products such as packaged goods, clothing, food, beverages and retail services. The Consumer Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Other Consideration for investing in Sigilon Stock

If you are still planning to invest in Sigilon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Sigilon Therapeutics' history and understand the potential risks before investing.
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences